2Año·

$OCGN (-6,13 %) Is there an entry opportunity now and is the correction coming? The forecast looks good. What do you think?

3 Comentarios

Ella M.@DividendenWaschbaer

2Año

The best time to start is always now

If you are convinced by the share.

•

Enrique@Dividenden_Monteur

2Año

And what is the investment case for the company?

••

Adam@InvestAdam

2Año

@Der_Dividenden_Monteur A gene therapy for the treatment of achromatopsia. Ocugen-001 is currently in Phase 3 trials and has the potential to be the first approved gene therapy for this rare disease. In addition, Ocugen-010 looks promising for the treatment of Usher syndrome. Ocugen also has strong partnerships with leading companies in ophthalmology, including Biogen and Astellas Pharma.

•